High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

Cutaneous T-cell lymphomas (CTCLs) are malignancies of skin-homing lymphoid cells, which have so far not been investigated thoroughly for common oncogenic mutations. We screened 90 biopsy specimens from CTCL patients (41 mycosis fungoides, 36 Sézary syndrome, and 13 non-mycosis fungoides/Sézary sy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kießling, Michael (VerfasserIn) , Oberholzer, Patrick A. (VerfasserIn) , Mondal, Chandrani (VerfasserIn) , Karpova, Maria B. (VerfasserIn) , Zipser, Marie C. (VerfasserIn) , Lin, William M. (VerfasserIn) , Girardi, Michael (VerfasserIn) , MacConaill, Laura E. (VerfasserIn) , Kehoe, Sarah M. (VerfasserIn) , Hatton, Charlie (VerfasserIn) , French, Lars E. (VerfasserIn) , Garraway, Levi A. (VerfasserIn) , Polier, Gernot (VerfasserIn) , Süss, Dorothee (VerfasserIn) , Klemke, Claus-Detlev (VerfasserIn) , Krammer, Peter H. (VerfasserIn) , Gülow, Karsten (VerfasserIn) , Dummer, Reinhard (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 5, 2011
In: Blood
Year: 2011, Jahrgang: 117, Heft: 8, Pages: 2433-2440
ISSN:1528-0020
DOI:10.1182/blood-2010-09-305128
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2010-09-305128
Volltext
Verfasserangaben:Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, Maria B. Karpova, Marie C. Zipser, William M. Lin, Michael Girardi, Laura E. MacConaill, Sarah M. Kehoe, Charlie Hatton, Lars E. French, Levi A. Garraway, Gernot Polier, Dorothee Süss, Claus-Detlev Klemke, Peter H. Krammer, Karsten Gülow, and Reinhard Dummer

MARC

LEADER 00000caa a2200000 c 4500
001 1812500017
003 DE-627
005 20220820234306.0
007 cr uuu---uuuuu
008 220801s2011 xx |||||o 00| ||eng c
024 7 |a 10.1182/blood-2010-09-305128  |2 doi 
035 |a (DE-627)1812500017 
035 |a (DE-599)KXP1812500017 
035 |a (OCoLC)1341464715 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kießling, Michael  |d 1979-  |e VerfasserIn  |0 (DE-588)138977445  |0 (DE-627)703170295  |0 (DE-576)309272068  |4 aut 
245 1 0 |a High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade  |c Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, Maria B. Karpova, Marie C. Zipser, William M. Lin, Michael Girardi, Laura E. MacConaill, Sarah M. Kehoe, Charlie Hatton, Lars E. French, Levi A. Garraway, Gernot Polier, Dorothee Süss, Claus-Detlev Klemke, Peter H. Krammer, Karsten Gülow, and Reinhard Dummer 
264 1 |c January 5, 2011 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.08.2022 
520 |a Cutaneous T-cell lymphomas (CTCLs) are malignancies of skin-homing lymphoid cells, which have so far not been investigated thoroughly for common oncogenic mutations. We screened 90 biopsy specimens from CTCL patients (41 mycosis fungoides, 36 Sézary syndrome, and 13 non-mycosis fungoides/Sézary syndrome CTCL) for somatic mutations using OncoMap technology. We detected oncogenic mutations for the RAS pathway in 4 of 90 samples. One mycosis fungoides and one pleomorphic CTCL harbored a KRASG13D mutation; one Sézary syndrome and one CD30+ CTCL harbored a NRASQ61K amino acid change. All mutations were found in stage IV patients (4 of 42) who showed significantly decreased overall survival compared with stage IV patients without mutations (P = .04). In addition, we detected a NRASQ61K mutation in the CTCL cell line Hut78. Knockdown of NRAS by siRNA induced apoptosis in mutant Hut78 cells but not in CTCL cell lines lacking RAS mutations. The NRASQ61K mutation sensitized Hut78 cells toward growth inhibition by the MEK inhibitors U0126, AZD6244, and PD0325901. Furthermore, we found that MEK inhibitors exclusively induce apoptosis in Hut78 cells. Taken together, we conclude that RAS mutations are rare events at a late stage of CTCL, and our preclinical results suggest that such late-stage patients profit from MEK inhibitors. 
700 1 |a Oberholzer, Patrick A.  |e VerfasserIn  |4 aut 
700 1 |a Mondal, Chandrani  |e VerfasserIn  |4 aut 
700 1 |a Karpova, Maria B.  |e VerfasserIn  |4 aut 
700 1 |a Zipser, Marie C.  |e VerfasserIn  |4 aut 
700 1 |a Lin, William M.  |e VerfasserIn  |4 aut 
700 1 |a Girardi, Michael  |e VerfasserIn  |4 aut 
700 1 |a MacConaill, Laura E.  |e VerfasserIn  |4 aut 
700 1 |a Kehoe, Sarah M.  |e VerfasserIn  |4 aut 
700 1 |a Hatton, Charlie  |e VerfasserIn  |4 aut 
700 1 |a French, Lars E.  |e VerfasserIn  |4 aut 
700 1 |a Garraway, Levi A.  |e VerfasserIn  |4 aut 
700 1 |a Polier, Gernot  |e VerfasserIn  |0 (DE-588)1022220977  |0 (DE-627)716938952  |0 (DE-576)364990627  |4 aut 
700 1 |a Süss, Dorothee  |e VerfasserIn  |4 aut 
700 1 |a Klemke, Claus-Detlev  |d 1969-  |e VerfasserIn  |0 (DE-588)122909615  |0 (DE-627)082229074  |0 (DE-576)293473145  |4 aut 
700 1 |a Krammer, Peter H.  |d 1946-  |e VerfasserIn  |0 (DE-588)121766373  |0 (DE-627)081520255  |0 (DE-576)292873417  |4 aut 
700 1 |a Gülow, Karsten  |e VerfasserIn  |0 (DE-588)1075033322  |0 (DE-627)832872008  |0 (DE-576)184768748  |4 aut 
700 1 |a Dummer, Reinhard  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Blood  |d Washington, DC : American Society of Hematology, 1946  |g 117(2011), 8, Seite 2433-2440  |h Online-Ressource  |w (DE-627)266886647  |w (DE-600)1468538-3  |w (DE-576)075961938  |x 1528-0020  |7 nnas  |a High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade 
773 1 8 |g volume:117  |g year:2011  |g number:8  |g pages:2433-2440  |g extent:8  |a High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade 
856 4 0 |u https://doi.org/10.1182/blood-2010-09-305128  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220801 
993 |a Article 
994 |a 2011 
998 |g 1075033322  |a Gülow, Karsten  |m 1075033322:Gülow, Karsten  |d 50000  |e 50000PG1075033322  |k 0/50000/  |p 17 
998 |g 121766373  |a Krammer, Peter H.  |m 121766373:Krammer, Peter H.  |d 50000  |e 50000PK121766373  |k 0/50000/  |p 16 
998 |g 122909615  |a Klemke, Claus-Detlev  |m 122909615:Klemke, Claus-Detlev  |d 60000  |e 60000PK122909615  |k 0/60000/  |p 15 
999 |a KXP-PPN1812500017  |e 4174695385 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2011","dateIssuedDisp":"January 5, 2011"}],"note":["Gesehen am 01.08.2022"],"physDesc":[{"extent":"8 S."}],"title":[{"title":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade","title_sort":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade"}],"person":[{"role":"aut","display":"Kießling, Michael","family":"Kießling","given":"Michael"},{"family":"Oberholzer","given":"Patrick A.","display":"Oberholzer, Patrick A.","role":"aut"},{"display":"Mondal, Chandrani","role":"aut","given":"Chandrani","family":"Mondal"},{"role":"aut","display":"Karpova, Maria B.","given":"Maria B.","family":"Karpova"},{"role":"aut","display":"Zipser, Marie C.","given":"Marie C.","family":"Zipser"},{"given":"William M.","family":"Lin","role":"aut","display":"Lin, William M."},{"family":"Girardi","given":"Michael","role":"aut","display":"Girardi, Michael"},{"given":"Laura E.","family":"MacConaill","display":"MacConaill, Laura E.","role":"aut"},{"display":"Kehoe, Sarah M.","role":"aut","family":"Kehoe","given":"Sarah M."},{"family":"Hatton","given":"Charlie","role":"aut","display":"Hatton, Charlie"},{"given":"Lars E.","family":"French","role":"aut","display":"French, Lars E."},{"role":"aut","display":"Garraway, Levi A.","family":"Garraway","given":"Levi A."},{"display":"Polier, Gernot","role":"aut","family":"Polier","given":"Gernot"},{"display":"Süss, Dorothee","role":"aut","family":"Süss","given":"Dorothee"},{"given":"Claus-Detlev","family":"Klemke","display":"Klemke, Claus-Detlev","role":"aut"},{"family":"Krammer","given":"Peter H.","display":"Krammer, Peter H.","role":"aut"},{"display":"Gülow, Karsten","role":"aut","family":"Gülow","given":"Karsten"},{"family":"Dummer","given":"Reinhard","display":"Dummer, Reinhard","role":"aut"}],"relHost":[{"titleAlt":[{"title":"Blood online"}],"disp":"High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascadeBlood","language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"text":"117(2011), 8, Seite 2433-2440","pages":"2433-2440","issue":"8","year":"2011","volume":"117","extent":"8"},"corporate":[{"role":"isb","display":"American Society of Hematology"}],"title":[{"subtitle":"journal of the American Society of Hematology","title_sort":"Blood","title":"Blood"}],"pubHistory":["1.1946 -"],"id":{"eki":["266886647"],"issn":["1528-0020"],"zdb":["1468538-3"]},"recId":"266886647","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1946-","publisher":"American Society of Hematology ; Saunders ; HighWire Press","publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedKey":"1946"}],"note":["Gesehen am 21.04.2023"]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Michael K. Kießling, Patrick A. Oberholzer, Chandrani Mondal, Maria B. Karpova, Marie C. Zipser, William M. Lin, Michael Girardi, Laura E. MacConaill, Sarah M. Kehoe, Charlie Hatton, Lars E. French, Levi A. Garraway, Gernot Polier, Dorothee Süss, Claus-Detlev Klemke, Peter H. Krammer, Karsten Gülow, and Reinhard Dummer"]},"language":["eng"],"recId":"1812500017","id":{"eki":["1812500017"],"doi":["10.1182/blood-2010-09-305128"]}} 
SRT |a KIESSLINGMHIGHTHROUG5201